Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Merus N.V. (MRUS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/12/2020 |
8-K
| Quarterly results |
| 12/01/2017 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Unaudited financial statements for Merus N.V. for the three and nine month periods ended September 30, 2017 and 2016",
"MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS UTRECHT, The Netherlands, November 30, 2017 — Merus N.V. , a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics , today announced financial results for the third quarter ended September 30, 2017 and provided a clinical update. “Merus continues to make meaningful advances with both our proprietary pipeline, led by MCLA-128, and our various collaboration programs,” said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. “We look forward to several milestones over the balance of the year, including our plan to initiate a Phase 2 clinical trial of MCLA-128 in combination with other therapies in HER2 positive and ER+/HER2 low metastatic breast cancer and plan to file a C..." |
|
| 09/22/2017 |
6-K
| Quarterly results |
| 07/11/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 04/28/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
|
|